Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 23;8(2):00640-2021.
doi: 10.1183/23120541.00640-2021. eCollection 2022 Apr.

ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly

Sabina A Guler  1 , Sara Cuevas-Ocaña  2 , Mouhamad Nasser  3 , Wim A Wuyts  4 , Marlies S Wijsenbeek  5 , Antoine Froidure  6 , Elena Bargagli  7 , Elisabetta A Renzoni  8 , Marcel Veltkamp  9   10 , Paolo Spagnolo  11 , Hilario Nunes  12 , Cormac McCarthy  13 , Maria Molina-Molina  14 , Francesco Bonella  15 , Venerino Poletti  16 , Michael Kreuter  17 , Katerina M Antoniou  18 , Catharina C Moor  5
Affiliations

ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly

Sabina A Guler et al. ERJ Open Res. .

Abstract

This article provides an overview of scientific highlights in the field of interstitial lung disease (ILD), presented at the virtual European Respiratory Society Congress 2021. A broad range of topics was discussed this year, ranging from translational and genetic aspects to novel innovations with the potential to improve the patient pathway. Early Career Members summarise a selection of interesting findings from different congress sessions, together with the leadership of Assembly 12 - Interstitial Lung Disease.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: S.A. Guler reports payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Boehringer Ingelheim and Hoffmann-La Roche; and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim (disclosures made outside the submitted work). Conflict of interest: S. Cuevas-Ocaña reports receiving support for attending meetings and/or travel from the ERS (disclosure made outside the submitted work). Conflict of interest: M. Nasser reports receiving consulting fees from Boehringer Ingelheim, AstraZeneca, Hoffman-La Roche and Chugai, outside the submitted work. Conflict of interest: W.A. Wuyts reports grants or contracts received form Roche, Boehringer Ingelheim, Galapagos, the NIH and Fund Scientific Research Flanders (disclosures made outside the submitted work). Conflict of interest: M.S. Wijsenbeek reports receiving grants or contracts from Hoffmann-La Roche and Boehringer Ingelheim; consulting fees from Roche, Boehringer Ingelheim, Galapagos, Bristol Myers Squibb, Galecto and Respivant; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Hoffmann-La Roche and Novartis; support for attending meetings and/or travel from Boehringer Ingelheim and Hoffmann-La Roche; and participation on a Data Safety Monitoring Board for Savara and Galapagos. Unpaid positions: Chair of the Idiopathic Interstitial Pneumonia Group of the ERS; member of the board of the Netherlands Respiratory Society; member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and Related Disorders Federation; Chair of the educational committee of the European Reference Network for Rare Lung Diseases; and advisory board of the Dutch lung fibrosis and sarcoidosis patient associations (disclosures made outside the submitted work). Conflict of interest: A. Froidure reports grants or contracts received from Roche and Boehringer Ingelheim; and consulting fees received from Boehringer Ingelheim and Roche (disclosures made outside the submitted work). Conflict of interest: E. Bargagli has nothing to disclose. Conflict of interest: E.A. Renzoni reports grants or contracts received from Boehringer Ingelheim; consulting fees received from Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Roche and Chiesi; and support for attending meetings and/or travel received from Boehringer Ingelheim (disclosures made outside the submitted work). Conflict of interest: M. Veltkamp reports receiving consulting fees from Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Chiesi Pharmaceutical; and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim and the COLD study (disclosures made outside the submitted work). Conflict of interest: P. Spagnolo reports grants or contracts received from PPM Services, Roche and Boehringer Ingelheim; consulting fees received from PPM Services, Chiesi, Novartis and Pieris; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Roche and Chiesi; support for attending meetings and/or travel received from PPM Services and Boehringer Ingelheim; and participation on a Data Safety Monitoring Board or Advisory Board for Galapagos (disclosures made outside the submitted work). Conflict of interest: H. Nunes reports receiving consulting fees from Boehringer Ingelheim, Roche and Genentech; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Roche and Genentech; support for attending meetings and/or travel received from Boehringer Ingelheim, Roche and Genentech; participation on a Data Safety Monitoring Board or Advisory Board for Galapagos and Actelion Pharmaceuticals; and was an investigator of clinical trials for Sanofi, Gilead, Novartis, Galecto Biotech AB and BMS (disclosures made outside the submitted work). Conflict of interest: C. McCarthy reports receiving grants or contracts from Boehringer Ingelheim; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Roche Ltd and Aerogen; support for attending meetings and/or travel received from Boehringer Ingelheim and Roche; and participation on a Data Safety Monitoring Board or Advisory Board for Savara Inc. (disclosures made outside the submitted work). Conflict of interest: M. Molina-Molina reports grants or contracts received from Roche and Boehringer Ingelheim; consulting fees received from Esteve-Teijin, Ferrer and Chiesi; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Boehringer Ingelheim; and support for attending meetings and/or travel received from Boehringer Ingelheim (disclosures made outside the submitted work). Conflict of interest: F. Bonella reports receiving consulting fees from Boehringer Ingelheim and Savara Pharma; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Boehringer Ingelheim, Fujirebio, Galapagos NV and Roche; support for attending meetings and/or travel received from Boehringer Ingelheim and Roche; and participation on a Data Safety Monitoring Board or Advisory Board for Boehringer Ingelheim, Bristol Myers Squibb, Fujirebio, Galapagos NV, GlaxoSmithKline, Roche and Takeda (disclosures made outside the submitted work). Conflict of interest: V. Poletti has nothing to disclose. Conflict of interest: M. Kreuter reports receiving grants or contracts from Roche and Boehringer Ingelheim; consulting fees received from Roche, Boehringer Ingelheim and Galapagos; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events received from Roche and Boehringer Ingelheim (disclosures made outside the submitted work). Conflict of interest: K.M. Antoniou reports receiving consulting fees from Boehringer Ingelheim and Roche; payment of honoraria for lectures, presentations, speakers’ bureaus, manuscript writing or educational events for Boehringer Ingelheim and Roche; and support for attending meetings and/or travel received from Boehringer Ingelheim and Roche; she is head of ERS Assembly 12 (disclosures made outside the submitted work). Conflict of interest: C.C. Moor reports receiving grants or contracts from Roche and Boehringer-Ingelheim; and speaker fees from Roche and Boehringer-Ingelheim. All grants and fees were paid to her institution (disclosures made outside the submitted work).

References

    1. Qiu L, Gong G, Zang G. A novel prognostic signature based on five-immune-related genes for idiopathic pulmonary fibrosis. Eur Respir J 2021; 58: Suppl. 65, OA4327. - PMC - PubMed
    1. Osuna Gómez R, Orozco Echevarria S, Millán Billi P, et al. . Profile of antimicrobial peptides in the bronchoalveolar lavage of patients with interstitial lung diseases. Eur Respir J 2021; 58: Suppl. 65, OA1208.
    1. Cruz T, Bondonese A, Sembrat J, et al. . Impaired lung NK activity in the lung of idiopathic pulmonary fibrosis patients. Eur Respir J 2021; 58: Suppl. 65, OA4332.
    1. Nishikiori H, Hirota K, Suzuki T, et al. . Validation of the artificial intelligence software to detect chronic fibrosing interstitial lung diseases in chest X-ray. Eur Respir J 2021; 58: Suppl. 65, OA1211.
    1. Bendstrup E, Wijsenbeek M, Valenzuela C, et al. . STARLINER study, disease behaviour assessed by a wide range of parameters including patient-reported outcomes (PRO) results. Eur Respir J 2021; 58: Suppl. 65, OA1207.